Exact Therapeutics AS (OSL:EXTX) EBIT : kr-48.30 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Exact Therapeutics AS EBIT?

Exact Therapeutics AS's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was kr-26.57 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was kr-48.30 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Exact Therapeutics AS's annualized ROC % for the quarter that ended in Dec. 2023 was -532.48%. Exact Therapeutics AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -1,099.47%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Exact Therapeutics AS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -26.33%.

Exact Therapeutics AS EBIT Historical Data

The historical data trend for Exact Therapeutics AS's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Therapeutics AS EBIT Chart

Exact Therapeutics AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-14.81

-33.06

-58.49

-40.47

-48.30

Exact Therapeutics AS Semi-Annual Data
	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	Get a 7-Day Free Trial						-22.59	-26.18	-14.29	-21.73	-26.57

Competitive Comparison of Exact Therapeutics AS's EBIT

For the Biotechnology subindustry, Exact Therapeutics AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exact Therapeutics AS's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exact Therapeutics AS's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Exact Therapeutics AS's EV-to-EBIT falls into.

Exact Therapeutics AS EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-48.30 Mil.

Exact Therapeutics AS (OSL:EXTX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Exact Therapeutics AS's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-52.258 * ( 1 - 0.19% )	/	( (7.454	+	12.137)	/ 2 )
=	-52.1587098	/	9.7955
=	-532.48 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	52.819	-	6.244	-	( 39.121	-	max(0, 6.763	-	48.574	+	39.121	))
=	7.454

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	61.319	-	8.769	-	( 45.573	-	max(0, 15.486	-	55.899	+	45.573	))
=	12.137

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Exact Therapeutics AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-53.132	/	( ( (4.245 + max(-5.959, 0))	+	(5.42 + max(-12.92, 0)) )	/	2 )
=	-53.132	/	( ( 4.245	+	5.42 )	/	2 )
=	-53.132	/	4.8325
=	-1,099.47 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.285)	-	(6.244	+	0	+	0)
=	-5.959

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.02)	-	(8.769	+	0	+	6.171)
=	-12.92

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Exact Therapeutics AS's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-48.296	/	183.394
	=	-26.33 %

Exact Therapeutics AS EBIT Related Terms

Thank you for viewing the detailed overview of Exact Therapeutics AS's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Exact Therapeutics AS (OSL:EXTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exact Therapeutics AS (OSL:EXTX) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ostre Aker vei 19, Oslo, NOR, 0581

Website

https://www.exact-tx.com

Exact Therapeutics AS is a clinical-stage biotechnology company. It is developing a technology platform for therapeutic enhancement - Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement that will amplify the clinical utility of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions.

Exact Therapeutics AS (OSL:EXTX) Headlines

No Headlines